To investigate the recent real-world use of first-generation antiandrogens (FGAs) in metastatic castration-resistant prostate cancer (mCRPC) using a retrospective multicentre cohort study.
The electronic CRPC Australian Database (ePAD) was interrogated to identify patients with mCRPC.